Stocks and Investing
Stocks and Investing
Tue, April 2, 2024
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Mon, April 1, 2024
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Li Watsek Reiterated (ASND) at Buy and Held Target at $173 on, Apr 1st, 2024
Li Watsek of Cantor Fitzgerald, Reiterated "Ascendis Pharma A/S" (ASND) at Buy and Held Target at $173 on, Apr 1st, 2024.
Li has made no other calls on ASND in the last 4 months.
There are 4 other peers that have a rating on ASND. Out of the 4 peers that are also analyzing ASND, 0 agree with Li's Rating of Hold.
These are the ratings of the 4 analyists that currently disagree with Li
- Derek Archila of "Wells Fargo" Maintained at Buy with Increased Target to $260 on, Friday, March 15th, 2024
- Andreas Argyrides of "Wedbush" Maintained at Buy with Increased Target to $225 on, Thursday, February 8th, 2024
- David Lebowitz of "Citigroup" Maintained at Strong Buy with Increased Target to $182 on, Thursday, February 8th, 2024
- Kelly Shi of "Jefferies" Initiated at Strong Buy and Held Target at $150 on, Wednesday, December 20th, 2023
Contributing Sources